{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:20:12Z","timestamp":1747207212367,"version":"3.40.5"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Genetic polymorphism of drug-metabolising enzymes and transporters may influence the\neffect and toxicity of antiretroviral drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>To determine and compare the minimum allele frequency of 20 single nucleotide polymorphisms\n(SNPs) with possible involvement in the metabolism of the antiretroviral drugs with other populations. To investigate\nthe influence of these variants on Reverse transcriptase, Protease and Integrase strand transfer inhibitor drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>DNA samples were collected from 1489 subjects. All SNPs with a gene call score of &gt; 0.6 were selected\nfor genotyping. The R package calculated call rates, MAF and Hardy-Weinberg equilibrium (HWE), test p-values,\nand Chi-squared analysis were performed on the data. The Fisher\u2019s exact test compared the allele frequencies\nbetween the populations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The highest similarities in minimum allele frequency (MAF) were between the Prospective Urban and\nRural Epidemiological group (PURE), a Black population in South Africa, and the Yoruba and Luhya populations\nin Africa.\nThe following SNPs were identified with a possible effect on metabolism: CYP2B6 rs28399494 (MAF 11%) is\nindicated in the toxicity of Efavirenz and Nevirapine. CYP3A5 rs776746 (MAF 17%) and CYP3A4 rs2749674\n(MAF 23%) both cause an increase in the metabolism of the protease inhibitors. The very low MAF values for\nboth SCL01B1 rs4149056 (MAF 0.6%) and ABCC rs717620 (MAF 2.8%) are indications that OATP1B1 transport\nfunction and glomerular filtration tempo will not be compromised. The high MAF value of 30% for UGTA1\nrs10929302 can result in hyperbilirubinemia, which can decrease the clearance of Dolutegravir.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These results show a possibility of kidney protection and an increase in bilirubin in this population.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892002255240231117072211","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T06:27:31Z","timestamp":1701066451000},"page":"700-708","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Certain Pharmacogenetic Differences on the Metabolism of\nAntiretroviral Drugs Used in A Black South African Population"],"prefix":"10.2174","volume":"24","author":[{"given":"Riaan","family":"Reay","sequence":"first","affiliation":[{"name":"Unit for Drug Research and Development, Division of Pharmacology, School of Pharmacy, North West University, Potchefstroom,\nSouth Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-3666","authenticated-orcid":true,"given":"Michelle","family":"Viljoen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, University of the Western Cape, Bellville,\nSouth Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-2663","authenticated-orcid":true,"given":"Malie","family":"Rheeders","sequence":"additional","affiliation":[{"name":"Unit for Drug Research and Development, Division of Pharmacology, School of Pharmacy, North West University, Potchefstroom,\nSouth Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.1038\/s41598-019-43736-z","volume":"9","author":"Afsar N.A.","year":"2019","unstructured":"Afsar N.A.; Bruckmueller H.; Werk A.N.; Nisar M.K.; Ahmad H.R.; Cascorbi I.; Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. Sci Rep  2019,9(1),7323","journal-title":"Sci Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fphar.2016.00396","volume":"7","author":"B\u00f6hm R.","year":"2016","unstructured":"B\u00f6hm R.; Cascorbi I.; Pharmacogenetics and predictive testing of drug hypersensitivity reactions. Front Pharmacol  2016,7(396),396","journal-title":"Front Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12688\/aasopenres.12965.1","volume":"2","author":"Dandara C.","year":"2019","unstructured":"Dandara C.; Masimirembwa C.; Haffani Y.Z.; Ogutu B.; Mabuka J.; Aklillu E.; Bolaji O.; African Pharmacogenomics Consortium Consolidating pharmacogenomics knowledge, capacity development and translation in Africa. AAS Open Res  2019,2,19","journal-title":"AAS Open Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2217\/pgs.11.106","volume":"12","author":"Dandara C.","year":"2011","unstructured":"Dandara C.; Lombard Z.; Du Plooy I.; McLellan T.; Norris S.A.; Ramsay M.; Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics  2011,12(12),1663-1670","journal-title":"Pharmacogenomics"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2217\/pme-2019-0110","volume":"17","author":"Radouani F.","year":"2020","unstructured":"Radouani F.; Zass L.; Hamdi Y.; Rocha J.; Sallam R.; Abdelhak S.; Ahmed S.; Azzouzi M.; Benamri I.; Benkahla A.; Bouhaouala-Zahar B.; Chaouch M.; Jmel H.; Kefi R.; Ksouri A.; Kumuthini J.; Masilela P.; Masimirembwa C.; Othman H.; Panji S.; Romdhane L.; Samtal C.; Sibira R.; Ghedira K.; Fadlelmola F.; Kassim S.K.; Mulder N.; A review of clinical pharmacogenetics studies in african populations. Per Med  2020,17(2),155-170","journal-title":"Per Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","volume":"17","author":"Rajman I.","year":"2017","unstructured":"Rajman I.; Knapp L.; Morgan T.; Masimirembwa C.; African genetic diversity: Implications for cytochrome p450-mediated drug metabolism and drug development. EBioMedicine  2017,17,67-74","journal-title":"EBioMedicine"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1479-7364-5-4-265","volume":"5","author":"Ikediobi O.","year":"2011","unstructured":"Ikediobi O.; Aouizerat B.; Xiao Y.; Gandhi M.; Gebhardt S.; Warnich L.; Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics  2011,5(4),265-282","journal-title":"Hum Genomics"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1469-1809.2010.00585.x","volume":"74","author":"Wright G.E.B.","year":"2010","unstructured":"Wright G.E.B.; Niehaus D.J.H.; Dr\u00f6gem\u00f6ller B.I.; Koen L.; Gaedigk A.; Warnich L.; Elucidation of CYP2D6 genetic diversity in a unique African population: Implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet  2010,74(4),340-350","journal-title":"Ann Hum Genet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.meegid.2015.08.003","volume":"35","author":"Paganotti G.M.","year":"2015","unstructured":"Paganotti G.M.; Russo G.; Sobze M.S.; Mayaka G.B.; Muthoga C.W.; Tawe L.; Martinelli A.; Romano R.; Vullo V.; CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon. Infect Genet Evol  2015,35,122-126","journal-title":"Infect Genet Evol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1146\/annurev-pharmtox-021320-111248","volume":"61","author":"Yu Z.J.","year":"2021","unstructured":"Yu Z.J.; Mosher E.P.; Bumpus N.N.; Pharmacogenomics of antiretroviral drug metabolism and transport. Annu Rev Pharmacol Toxicol  2021,61(1),565-585","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ijid.2020.12.009","volume":"104","author":"Pallerla S.R.","year":"2021","unstructured":"Pallerla S.R.; Elion Assiana D.O.; Linh L.T.K.; Cho F.N.; Meyer C.G.; Fagbemi K.A.; Adegnika A.A.; Beng V.P.; Achidi E.A.; Kahunu G.M.; Bates M.; Grobusch M.P.; Kremsner P.G.; Ntoumi F.; Velavan T.P.; Pharmacogenetic considerations in the treatment of co-infections with HIV\/AIDS, tuberculosis and malaria in Congolese populations of Central Africa. Int J Infect Dis  2021,104,207-213","journal-title":"Int J Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/tpj.2013.13","volume":"14","author":"Aminkeng F.","year":"2014","unstructured":"Aminkeng F.; Ross C.J.D.; Rassekh S.R.; Brunham L.R.; Sistonen J.; Dube M-P.; Ibrahim M.; Nyambo T.B.; Omar S.A.; Froment A.; Bodo J-M.; Tishkoff S.; Carleton B.C.; Hayden M.R.; Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J  2014,14(2),160-170","journal-title":"Pharmacogenomics J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","volume":"23","author":"Swart M.","year":"2013","unstructured":"Swart M.; Skelton M.; Ren Y.; Smith P.; Takuva S.; Dandara C.; High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV\/AIDS patients. Pharmacogenet Genomics  2013,23(8),415-427","journal-title":"Pharmacogenet Genomics"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/omi.2018.0117","volume":"22","author":"O\u2019Connell K.S.","year":"2018","unstructured":"O\u2019Connell K.S.; Swart M.; McGregor N.W.; Dandara C.; Warnich L.; Pharmacogenetics of antiretroviral drug response and pharmacokinetic variations in indigenous south african populations. OMICS  2018,22(9),589-597","journal-title":"OMICS"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrg865","volume":"3","author":"Tishkoff S.A.","year":"2002","unstructured":"Tishkoff S.A.; Williams S.M.; Genetic analysis of African populations: Human evolution and complex disease. Nat Rev Genet  2002,3(8),611-621","journal-title":"Nat Rev Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s002280100282","volume":"57","author":"Dandara C.","year":"2001","unstructured":"Dandara C.; Mutowembwa Masimirembwa C.; Magimba A.; Sayi J.; Kaaya S.; Sommers D.K.; Snyman J.R.; Hasler J.A.; Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. Eur J Clin Pharmacol  2001,57(1),11-17","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2012.45","volume":"13","author":"Sim S.C.","year":"2013","unstructured":"Sim S.C.; Kacevska M.; Ingelman-Sundberg M.; Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J  2013,13(1),1-11","journal-title":"Pharmacogenomics J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cpt.690","volume":"102","author":"Zhou Y.","year":"2017","unstructured":"Zhou Y.; Ingelman-Sundberg M.; Lauschke V.M.; Worldwide distribution of cytochrome P450 alleles: A meta\u2010analysis of population\u2010scale sequencing projects. Clin Pharmacol Ther  2017,102(4),688-700","journal-title":"Clin Pharmacol Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41397-021-00209-9","volume":"21","author":"Badary O.A.","year":"2021","unstructured":"Badary O.A.; Pharmacogenomics and COVID-19: Clinical implications of human genome interactions with repurposed drugs. Pharmacogenomics J  2021,21(3),275-284","journal-title":"Pharmacogenomics J"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12879-017-2717-x","volume":"17","author":"Yagura H.","year":"2017","unstructured":"Yagura H.; Watanabe D.; Kushida H.; Tomishima K.; Togami H.; Hirano A.; Takahashi M.; Hirota K.; Ikuma M.; Kasai D.; Nishida Y.; Yoshino M.; Yamazaki K.; Uehira T.; Shirasaka T.; Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis  2017,17(1),622","journal-title":"BMC Infect Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1124\/dmd.119.089052","volume":"48","author":"Collins K.S.","year":"2020","unstructured":"Collins K.S.; Metzger I.F.; Gufford B.T.; Lu J.B.; Medeiros E.B.; Pratt V.M.; Skaar T.C.; Desta Z.; Influence of uridine diphosphate glucuronosyltransferase family 1 member A1 and solute carrier organic anion transporter family 1 member B1 polymorphisms and efavirenz on bilirubin disposition in healthy volunteers. Drug Metab Dispos  2020,48(3),169-175","journal-title":"Drug Metab Dispos"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.3390\/ijms21186627","volume":"21","author":"Zazuli Z.","year":"2020","unstructured":"Zazuli Z.; Duin N.J.C.B.; Jansen K.; Vijverberg S.J.H.; Maitland-van der Zee A.H.; Masereeuw R.; The impact of genetic polymorphisms in organic cation transporters on renal drug disposition. Int J Mol Sci  2020,21(18),6627","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ebiom.2015.07.008","volume":"2","author":"Lade J.M.","year":"2015","unstructured":"Lade J.M.; To E.E.; Hendrix C.W.; Bumpus N.N.; Discovery of genetic variants of the kinases that activate tenofovir in a compartment-specific manner. EBioMedicine  2015,2(9),1145-1152","journal-title":"EBioMedicine"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/pgs-2018-0140","volume":"20","author":"Hamlin A.N.","year":"2019","unstructured":"Hamlin A.N.; Tillotson J.; Bumpus N.N.; Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir. Pharmacogenomics  2019,20(2),105-111","journal-title":"Pharmacogenomics"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e0195764","DOI":"10.1371\/journal.pone.0195764","volume":"13","author":"Figueroa D.B.","year":"2018","unstructured":"Figueroa D.B.; Tillotson J.; Li M.; Piwowar-Manning E.; Hendrix C.W.; Holtz T.H.; Bokoch K.; Bekker L.G.; van Griensven F.; Mannheimer S.; Hughes J.P.; Grant R.M.; Bumpus N.N.; Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067. PLoS One  2018,13(4),e0195764","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/508546","volume":"194","author":"Izzedine H.","year":"2006","unstructured":"Izzedine H.; Hulot J.S.; Villard E.; Goyenvalle C.; Dominguez S.; Ghosn J.; Valantin M.A.; Lechat P.; Deray G.; Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis  2006,194(11),1481-1491","journal-title":"J Infect Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1128\/AAC.00512-10","volume":"54","author":"Chou M.","year":"2010","unstructured":"Chou M.; Bertrand J.; Segeral O.; Verstuyft C.; Borand L.; Comets E.; Le Tiec C.; Becquemont L.; Ouk V.; Mentre F.; Taburet A.M.; Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother  2010,54(10),4432-4439","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1089\/omi.2017.0078","volume":"21","author":"Reay R.","year":"2017","unstructured":"Reay R.; Dandara C.; Viljoen M.; Rheeders M.; CYP2B6 haplotype predicts efavirenz plasma concentration in black South African HIV-1-infected children: A longitudinal pediatric pharmacogenomic study. OMICS  2017,21(8),465-473","journal-title":"OMICS"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fgene.2015.00356","volume":"6","author":"Swart M.","year":"2016","unstructured":"Swart M.; Evans J.; Skelton M.; Castel S.; Wiesner L.; Smith P.J.; Dandara C.; An expanded analysis of pharmacogenetics determinants of efavirenz response that includes 3\u2032-UTR single nucleotide polymorphisms among Black South African HIV\/AIDS patients. Front Genet  2016,6,356","journal-title":"Front Genet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bcp.12590","volume":"80","author":"Sinxadi P.Z.","year":"2015","unstructured":"Sinxadi P.Z.; Leger P.D.; McIlleron H.M.; Smith P.J.; Dave J.A.; Levitt N.S.; Maartens G.; Haas D.W.; Pharmacogenetics of plasma efavirenz exposure in HIV\u2010infected adults and children in South Africa. Br J Clin Pharmacol  2015,80(1),146-156","journal-title":"Br J Clin Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature15817","volume":"526","author":"Relling M.V.","year":"2015","unstructured":"Relling M.V.; Evans W.E.; Pharmacogenomics in the clinic. Nature  2015,526(7573),343-350","journal-title":"Nature"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2217\/pgs.10.90","volume":"11","author":"Dr\u00f6gem\u00f6ller B.I.","year":"2010","unstructured":"Dr\u00f6gem\u00f6ller B.I.; Wright G.E.B.; Niehaus D.J.H.; Koen L.; Malan S.; Da Silva D.M.; Hillermann-Rebello R.; La Grange A.M.; Venter M.; Warnich L.; Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics  2010,11(8),1095-1103","journal-title":"Pharmacogenomics"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bcp.12639","volume":"80","author":"Zhang J.","year":"2015","unstructured":"Zhang J.; Hayes S.; Sadler B.M.; Minto I.; Brandt J.; Piscitelli S.; Min S.; Song I.H.; Population pharmacokinetics of dolutegravir in HIV\u2010infected treatment\u2010naive patients. Br J Clin Pharmacol  2015,80(3),502-514","journal-title":"Br J Clin Pharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1017\/S1368980018001118","volume":"21","author":"Wentzel-Viljoen E.","year":"2018","unstructured":"Wentzel-Viljoen E.; Lee S.; Laubscher R.; Vorster H.H.; Accelerated nutrition transition in the North West Province of South Africa: Results from the prospective Urban and Rural epidemiology (PURE-NWP-SA) cohort study, 2005 to 2010. Public Health Nutr  2018,21(14),2630-2641","journal-title":"Public Health Nutr"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.4102\/sajs.v107i11\/12.395","author":"Mbongwa HP","year":"2011","unstructured":"Mbongwa HP; Pretorius PJ; Kruger A; Koekemoer G; Reinecke CJ;  Single nucleotide and copy number polymorphisms of the SULT1A1 gene in a South African Tswana population group  2011","journal-title":"Single nucleotide and copy number polymorphisms of the SULT1A1 gene in a South African Tswana population group"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2009.04.019","volume":"158","author":"Teo K.","year":"2009","unstructured":"Teo K.; Chow C.K.; Vaz M.; Rangarajan S.; Yusuf S.; The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. American heart journal  2009,158(1),1-7.e1","journal-title":"American heart journal"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1590\/S1415-47572014005000002","volume":"37","author":"Jacobs C.","year":"2014","unstructured":"Jacobs C.; Pearce B.; Du Plessis M.; Hoosain N.; Benjeddou M.; Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa. Genet Mol Biol  2014,37(2),350-359","journal-title":"Genet Mol Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.tpj.6500374","volume":"6","author":"Rodr\u00edguez-N\u00f3voa S.","year":"2006","unstructured":"Rodr\u00edguez-N\u00f3voa S.; Barreiro P.; Jim\u00e9nez-N\u00e1cher I.; Soriano V.; Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J  2006,6(4),234-245","journal-title":"Pharmacogenomics J"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/jac\/dkn029","volume":"61","author":"Wyen C.","year":"2008","unstructured":"Wyen C.; Hendra H.; Vogel M.; Hoffmann C.; Knechten H.; Brockmeyer N.H.; Bogner J.R.; Rockstroh J.; Esser S.; Jaeger H.; Harrer T.; Mauss S.; van Lunzen J.; Skoetz N.; Jetter A.; Groneuer C.; F\u00e4tkenheuer G.; Khoo S.H.; Egan D.; Back D.J.; Owen A.; Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother  2008,61(4),914-918","journal-title":"J Antimicrob Chemother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5501\/wjv.v4.i3.198","volume":"4","author":"Aceti A.","year":"2015","unstructured":"Aceti A.; Gianserra L.; Lambiase L.; Pennica A.; Teti E.; Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virol  2015,4(3),198-208","journal-title":"World J Virol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00228-009-0660-5","volume":"65","author":"Bertrand J.","year":"2009","unstructured":"Bertrand J.; Treluyer J.M.; Panhard X.; Tran A.; Auleley S.; Rey E.; Salmon-C\u00e9ron D.; Duval X.; Mentr\u00e9 F.; Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol  2009,65(7),667-678","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/FPC.0000000000000169","volume":"25","author":"da Rocha I.M.","year":"2015","unstructured":"da Rocha I.M.; Gasparotto A.S.; Lazzaretti R.K.; Notti R.K.; Sprinz E.; Mattevi V.S.; Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort. Pharmacogenet Genomics  2015,25(11),541-547","journal-title":"Pharmacogenet Genomics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/jpm11030204","volume":"11","author":"Zubiaur P.","year":"2021","unstructured":"Zubiaur P.; Benedicto M.D.; Villapalos-Garc\u00eda G.; Navares-G\u00f3mez M.; Mej\u00eda-Abril G.; Rom\u00e1n M.; Mart\u00edn-V\u00edlchez S.; Ochoa D.; Abad-Santos F.; SLCO1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability. J Pers Med  2021,11(3),204","journal-title":"J Pers Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/ckj\/sfac120","volume":"15","author":"Park S.","year":"2022","unstructured":"Park S.; Lee S.; Kim Y.; Lee Y.; Kang M.W.; Kim K.; Kim Y.C.; Han S.S.; Lee H.; Lee J.P.; Joo K.W.; Lim C.S.; Kim Y.S.; Kim D.K.; Serum bilirubin and kidney function: A Mendelian randomization study. Clin Kidney J  2022,15(9),1755-1762","journal-title":"Clin Kidney J"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1469-1809.2010.00638.x","volume":"75","author":"Horsfall L.J.","year":"2011","unstructured":"Horsfall L.J.; Zeitlyn D.; Tarekegn A.; Bekele E.; Thomas M.G.; Bradman N.; Swallow D.M.; Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet  2011,75(2),236-246","journal-title":"Ann Hum Genet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1093\/jac\/dku304","volume":"69","author":"Nishijima T.","year":"2014","unstructured":"Nishijima T.; Tsuchiya K.; Tanaka N.; Joya A.; Hamada Y.; Mizushima D.; Aoki T.; Watanabe K.; Kinai E.; Honda H.; Yazaki H.; Tanuma J.; Tsukada K.; Teruya K.; Kikuchi Y.; Oka S.; Gatanaga H.; Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3\u2032 untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: A pharmacogenetic study. J Antimicrob Chemother  2014,69(12),3320-3328","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002255240231117072211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223789\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002255240231117072211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:12:20Z","timestamp":1706865140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223789\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002255240231117072211","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}